TY - JOUR
T1 - Targeting angiopoietin-2 as a novel treatment option for kidney fibrosis
AU - Samuel, Chrishan S.
N1 - Funding Information:
CSS is supported by a Senior Research Fellowship from the Monash Biomedicine Discovery Institute.
Publisher Copyright:
© 2022 International Society of Nephrology
PY - 2022/10
Y1 - 2022/10
N2 - Kidney fibrosis is a hallmark of chronic kidney disease yet is poorly treated. Chang et al. determined that plasma and kidney levels of the vascular growth factor, angiopoietin-2, were elevated in patients with chronic kidney disease and mice with kidney disease. Angiopoietin-2 inhibited the renoprotective effects of angiopoietin-1 and promoted CC chemokine ligand 2–mediated kidney damage, endothelial cell apoptosis, vascular rarefaction, inflammation, fibrosis, and kidney dysfunction. Hence, therapeutically inhibiting angiopoietin-2 may represent a novel means of treating these chronic kidney disease–associated pathologies.
AB - Kidney fibrosis is a hallmark of chronic kidney disease yet is poorly treated. Chang et al. determined that plasma and kidney levels of the vascular growth factor, angiopoietin-2, were elevated in patients with chronic kidney disease and mice with kidney disease. Angiopoietin-2 inhibited the renoprotective effects of angiopoietin-1 and promoted CC chemokine ligand 2–mediated kidney damage, endothelial cell apoptosis, vascular rarefaction, inflammation, fibrosis, and kidney dysfunction. Hence, therapeutically inhibiting angiopoietin-2 may represent a novel means of treating these chronic kidney disease–associated pathologies.
UR - http://www.scopus.com/inward/record.url?scp=85137639834&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2022.07.023
DO - 10.1016/j.kint.2022.07.023
M3 - Comment / Debate
C2 - 36150760
AN - SCOPUS:85137639834
SN - 0085-2538
VL - 102
SP - 691
EP - 694
JO - Kidney International
JF - Kidney International
IS - 4
ER -